the organism company ginkgo bioworks engineers new organisms to solve challenges across a range of industries from fuels to pharmaceutical production. our biological engineers make use of an in-house pipeline of synthetic biology technologies to design, build, and test new organisms.
Company profile
Ticker
DNA
Exchange
Website
Employees
Incorporated
Location
Fiscal year end
Industry (SIC)
AMGEN • Gilead Sciences • Biogen • Qiagen • Moderna • BioNTech SE • Bio-Techne • Sana Biotechnology • Acorda Therapeutics • Exelixis ...
Former names
Soaring Eagle Acquisition Corp., Spinning Eagle Acquisition Corp.
SEC CIK
Corporate docs
Subsidiaries
Ginkgo Bioworks, Inc. • Ginkgo Bioworks Securities Corporation • Concentric by Ginkgo, LLC • Ginkgo International Holdings, Inc. • Concentric Consultancy QFZ LLC ...
DNA stock data
Latest filings (excl ownership)
S-3
Shelf registration
9 May 24
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
Ginkgo Bioworks Reports First Quarter 2024 Financial Results
9 May 24
ARS
2023 FY
Annual report to shareholders
29 Apr 24
DEFA14A
Additional proxy soliciting materials
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
8-K
Changes in Registrant's Certifying Accountant
14 Mar 24
S-8
Registration of securities for employees
1 Mar 24
10-K
2023 FY
Annual report
29 Feb 24
8-K
Ginkgo Bioworks Reports Fourth Quarter and Full Year 2023 Financial Results
29 Feb 24
Transcripts
DNA
Earnings call transcript
2024 Q1
9 May 24
DNA
Earnings call transcript
2023 Q3
8 Nov 23
DNA
Earnings call transcript
2023 Q2
9 Aug 23
DNA
Earnings call transcript
2023 Q1
10 May 23
DNA
Earnings call transcript
2022 Q4
1 Mar 23
DNA
Earnings call transcript
2022 Q3
15 Nov 22
DNA
Earnings call transcript
2022 Q2
16 Aug 22
DNA
Earnings call transcript
2022 Q1
17 May 22
DNA
Earnings call transcript
2021 Q4
29 Mar 22
DNA
Earnings call transcript
2021 Q3
15 Nov 21
Latest ownership filings
144
Notice of proposed sale of securities
10 May 24
144
Notice of proposed sale of securities
9 May 24
144
Notice of proposed sale of securities
8 May 24
144
Notice of proposed sale of securities
7 May 24
4
Mark E. Dmytruk
6 May 24
4
Steven P. Coen
6 May 24
144
Notice of proposed sale of securities
6 May 24
144
Notice of proposed sale of securities
3 May 24
144
Notice of proposed sale of securities
2 May 24
144
Notice of proposed sale of securities
2 May 24
Financial summary
Quarter (USD) | Sep 23 | Jun 23 | Mar 23 | Dec 22 | |
---|---|---|---|---|---|
Revenue | |||||
Cost of revenue | |||||
Operating income | |||||
Operating margin | |||||
Net income | |||||
Net profit margin | |||||
Cash on hand | |||||
Change in cash | |||||
Diluted EPS |
Annual (USD) | Dec 22 | Dec 21 | |
---|---|---|---|
Revenue | |||
Cost of revenue | |||
Operating income | |||
Operating margin | |||
Net income | |||
Net profit margin | |||
Cash on hand | |||
Change in cash | |||
Diluted EPS |
Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
---|---|---|---|---|---|---|
Cash on hand (at last report) | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn | 1.09 bn |
Cash burn (monthly) | 25.81 mm | 20.91 mm | 100.97 mm | 77.81 mm | 24.52 mm | 28.52 mm |
Cash used (since last report) | 190.13 mm | 153.99 mm | 743.67 mm | 573.06 mm | 180.57 mm | 210.03 mm |
Cash remaining | 904.49 mm | 940.63 mm | 350.95 mm | 521.56 mm | 914.05 mm | 884.59 mm |
Runway (months of cash) | 35.0 | 45.0 | 3.5 | 6.7 | 37.3 | 31.0 |
Institutional ownership, Q4 2023
73.7% owned by funds/institutions
13F holders | Current |
---|---|
Total holders | 261 |
Opened positions | 36 |
Closed positions | 112 |
Increased positions | 74 |
Reduced positions | 76 |
13F shares | Current |
---|---|
Total value | 1.85 tn |
Total shares | 1.25 bn |
Total puts | 205.10 k |
Total calls | 220.50 k |
Total put/call ratio | 0.9 |
Largest owners | Shares | Value |
---|---|---|
Baillie Gifford & Co | 236.29 mm | $399.33 bn |
ARK Investment Management | 198.61 mm | $335.65 bn |
Cascade Investment, L.L.C. | 151.87 mm | $1.73 bn |
Viking Global Investors | 143.09 mm | $241.81 bn |
Vanguard | 132.78 mm | $224.40 bn |
Anchorage Capital Group, L.L.C. | 69.85 mm | $118.05 bn |
CMTDF Sumitomo Mitsui Trust | 58.24 mm | $98.42 bn |
Nikko Asset Management Americas | 58.24 mm | $97.84 bn |
MS Morgan Stanley | 48.96 mm | $82.75 bn |
STT State Street | 26.05 mm | $44.03 bn |
Recent insider trades
Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
---|---|---|---|---|---|---|---|---|---|---|
2 May 24 | Steven P. Coen | Class A Common Stock | Sell | Dispose S | No | No | 0 | 131,928 | 0.00 | 162,527 |
2 May 24 | Mark E. Dmytruk | Class A Common Stock | Sell | Dispose S | No | No | 0 | 47,806 | 0.00 | 925,400 |
1 May 24 | Steven P. Coen | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 12,500 | 0.00 | 294,455 |
1 May 24 | Steven P. Coen | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 281,955 | 0.00 | 281,955 |
1 May 24 | Steven P. Coen | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 12,500 | 0.00 | 287,500 |
1 May 24 | Steven P. Coen | RSU Class A Common Stock | Option exercise | Dispose M | No | No | 0 | 281,955 | 0.00 | 845,865 |
1 May 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 1,635 | 0.00 | 973,206 |
1 May 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 22,917 | 0.00 | 971,571 |
1 May 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 18,125 | 0.00 | 948,654 |
1 May 24 | Mark E. Dmytruk | Class A Common Stock | Option exercise | Acquire M | No | No | 0 | 65,450 | 0.00 | 930,529 |
News
Why Diodes Shares Are Trading Lower By Around 10%? Here Are Other Stocks Moving In Friday's Mid-Day Session
10 May 24
William Blair Downgrades Ginkgo Bioworks Holdings to Underperform
10 May 24
Akamai Technologies Issues Weak Outlook, Joins Applied Optoelectronics, JFrog And Other Big Stocks Moving Lower In Friday's Pre-Market Session
10 May 24
Ginkgo Bioworks Stock Falls On Disappointing Q1 Sales: 'This Trend Needs To Change'
9 May 24
Ginkgo Bioworks Holdings Q1 2024 GAAP EPS $(0.08) Beats $(0.09) Estimate, Sales $38.000M Miss $46.044M Estimate
9 May 24
Press releases
Ginkgo Bioworks Reports First Quarter 2024 Financial Results
9 May 24
GreenLab Partners with Ginkgo Bioworks to Scale Up Production of Brazzein, a Novel Sweetener
7 May 24
Ginkgo Bioworks Announces Presentations at the Upcoming American Society of Gene & Cell Therapy (ASGCT) Annual Meeting
6 May 24
Ginkgo Bioworks Announces Date of First Quarter 2024 Results Presentation
2 May 24
WiSA Technologies (NASDAQ: WISA) Set to Revolutionize Home Audio: Strategic Moves and New Partnerships Signal Strong Market Position
30 Apr 24